$48.23
-0.51-1.04%
Últ. Act.: Oct 29, 10:59 AM
GSK (GSK) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
GSK (GSK) publicó su última previsión de octubre 28, 2026 para fiscal year 2031. La compañía estimó ingresos en un rango de para el período.
En comparación con la previsión anterior, GSK mantenido redujo su previsión de ingresos desde un rango anterior de $44.75B - $44.75B.
GSK ha emitido 17 actualizaciones de orientación entre el noviembre 2, 2022 y el octubre 28, 2026. During this period, the company raised its outlook 6 times and lowered it 5 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.40 | $1.27 | $1.17 | $0.64 |
| Actual | $1.47 | $1.35 | $1.25 | $0.68 |
| Surprise | +4.86% | +6.61% | +6.84% | +6.25% |
| Revenue | ||||
| Estimate | $11.80B | $10.79B | $10.19B | $11.19B |
| Actual | $11.95B | $11.28B | $10.30B | $11.46B |
| Surprise | +1.25% | +4.54% | +1.07% | +2.41% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.78 | $1.27 | $1.35 | $1.54 |
| Revenue | ||||
| Consensus | $12.09B | — | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 28, 2026 | $1.47 | $1.40 | 4.86 % |
| Q2 | Jul 28, 2026 | $1.35 | $1.27 | 6.61 % |
| Q1 | Apr 29, 2026 | $1.25 | $1.17 | 6.84 % |
| Q4 | Feb 4, 2026 | $0.68 | $0.64 | 6.25 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 28, 2026 | $11.95B | $11.80B | 1.25 % |
| Q2 | Jul 28, 2026 | $11.28B | $10.79B | 4.54 % |
| Q1 | Apr 29, 2026 | $10.30B | $10.19B | 1.07 % |
| Q4 | Feb 4, 2026 | $11.46B | $11.19B | 2.41 % |